Neumora's lead asset, Navacaprant, shows weak efficacy in phase 2 trial. Read why we are not optimistic about NMRA's prospects and rate the stock a Sell.
Jim Harbaugh listened to his heart when he began to feel a little bit off in pregame warmups. The Los Angeles Chargers coach went into the medical tent and then to the locker room in ...